Induction chemotherapy in head and neck cancers: Results and controversies
| Autor: | Thibaut Reverdy, Andy Karabajakian, Jérôme Fayette, Eve-Marie Neidhardt, Max Gau |
|---|---|
| Přispěvatelé: | Centre régional de lutte contre le cancer |
| Jazyk: | angličtina |
| Rok vydání: | 2019 |
| Předmět: |
Oncology
Cancer Research medicine.medical_specialty medicine.medical_treatment [SDV]Life Sciences [q-bio] Cetuximab Laryngectomy Docetaxel 03 medical and health sciences 0302 clinical medicine Internal medicine Antineoplastic Combined Chemotherapy Protocols Humans Medicine 030223 otorhinolaryngology Neoplasm Staging Randomized Controlled Trials as Topic Squamous Cell Carcinoma of Head and Neck business.industry Standard treatment Head and neck cancer Induction chemotherapy Cancer Chemoradiotherapy Induction Chemotherapy Immunotherapy medicine.disease Head and neck squamous-cell carcinoma Progression-Free Survival 3. Good health Regimen Head and Neck Neoplasms 030220 oncology & carcinogenesis Fluorouracil Cisplatin Larynx Oral Surgery business Organ Sparing Treatments medicine.drug |
| Zdroj: | Oral Oncology Oral Oncology, Elsevier, 2019, 95, pp.164-169. ⟨10.1016/j.oraloncology.2019.06.015⟩ |
| ISSN: | 1368-8375 |
| DOI: | 10.1016/j.oraloncology.2019.06.015⟩ |
| Popis: | Standard treatment for locally advanced head and neck squamous cell carcinoma (LAHNSCC) consists mainly of concurrent chemoradiation (CCR) but induction chemotherapy (IC) by docetaxel-cisplatin-fluorouracil (TPF), followed by CCR, is a strong option. Comparative trials suggest that IC and CCR are equivalent, and some trials suggest superiority of IC, whereas none shows inferiority. IC might have less interest in oropharyngeal cancer (more often linked to HPV infection). When functional laryngeal preservation is the patient's priority, essays strongly suggest that IC is the best treatment. There is little data about a less toxic regimen of IC, but several schemes are promising and need to be developed. An early selection of responders to IC by metabolic imaging must be considered. Intensification attempts with cetuximab were too toxic and unsafe, but trials with immunotherapy are ongoing to enhance TPF efficacy. After IC, CCR either with cetuximab or cisplatin seems to be equally effective. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect